The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

1 (tie), Lauren Coughlin, Georgia Hall, Minjee Lee, Madelene Sagstrom, Maja Stark and Angel Yin, 2. 7, 33 tied with 1. 1 (tie), Jaravee Boonchant, In Gee Chun, Danielle Kang, Ruixin Liu, Ryann O'Toole ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...